AstraZeneca presented new data underpinning the safety profile of Farxiga (dapagliflozin) with an analysis of data pooled from dapagliflozin clinical...
AstraZeneca and Bristol-Myers Squibb Company announced that the FDA has acknowledged receipt of the New Drug Application (NDA) resubmission for...
These updated data-derived and consensus-derived recommendations will help rheumatologists to manage patients with SSc in an evidence-based way. These recommendations also give directions for future clinical research in SSc.
To update and expand the 2013 Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the ICU.
The National Institute for Health and Care Excellence (NICE) has recommended Forxiga (dapagliflozin) from AstraZeneca as part of a triple...
The FDA has issued a Complete Response Letter regarding the New Drug Application for investigational compound dapagliflozin from BMS/AstraZeneca for...
AstraZeneca has announced results from a Phase III study evaluating the investigational combination of saxagliptin/dapagliflozin as a dual add-on therapy...
AstraZeneca and BMS announced results from a Phase III study evaluating dapagliflozin (Forxiga in EU) in adult patients with Type...
In the Dapagliflozin And Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized placebo-controlled trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin significantly reduced risk of kidney failure and prolonged survival in CKD patients with or without type 2 diabetes
The purpose of the study is to assess efficacy, safety and tolerability of treatment with zibotentan and dapagliflozin in combination and alone, compared with placebo in participants with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) between 20 and 60 mL/min/1.73m2.